These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 10975587)
81. [Prediction of restenosis after percutaneous transluminal coronary angioplasty using coronary flow reserve. Kansai Doppler Guide Wire Study Group]. Toda I; Teragaki M; Nishida Y; Kobayashi Y; Shimada K; Yoshiyama M; Akioka K; Takeuchi K; Yoshikawa J J Cardiol; 2000 Mar; 35(3):165-73. PubMed ID: 10808423 [TBL] [Abstract][Full Text] [Related]
82. Progression of coronary artery disease in patients receiving percutaneous transluminal coronary angioplasty: angiographic comparison of angioplasty and non-angioplasty sites. Ohtani R; Hiasa Y Intern Med; 1995 Jul; 34(7):611-7. PubMed ID: 7496068 [TBL] [Abstract][Full Text] [Related]
83. Effects of ketanserin on epicardial coronary arteries after coronary angioplasty in patients with stable angina. Tousoulis D; Davies G; Tentolouris C; Apostolopoulos T; Kyriakides M; Toutouzas P Eur Heart J; 1994 Jul; 15(7):922-7. PubMed ID: 7925513 [TBL] [Abstract][Full Text] [Related]
84. Randomized trial of late elective angioplasty versus conservative management for patients with residual stenoses after thrombolytic treatment of myocardial infarction. Treatment of Post-Thrombolytic Stenoses (TOPS) Study Group. Ellis SG; Mooney MR; George BS; da Silva EE; Talley JD; Flanagan WH; Topol EJ Circulation; 1992 Nov; 86(5):1400-6. PubMed ID: 1423952 [TBL] [Abstract][Full Text] [Related]
85. Effect of doxazosin on arterial elasticity: functional versus structural changes. Bratteli CW; Glasser SP J Clin Pharmacol; 2002 Oct; 42(10):1105-8. PubMed ID: 12362924 [TBL] [Abstract][Full Text] [Related]
86. Parameters of cell energy metabolism during stress in laboratory animals and energotropic effect of alpha1-adrenoblocker doxazosin. Vishnevskii EL; Vishnevskii AE; Shabel'nikova EI; Safronova ON; Dreval AA; Topchieva GV; Sukhorukov VS Bull Exp Biol Med; 2004 Nov; 138(5):440-1. PubMed ID: 15723120 [TBL] [Abstract][Full Text] [Related]
87. Ischemia and No Obstructive Coronary Artery Disease (INOCA): Developing Evidence-Based Therapies and Research Agenda for the Next Decade. Bairey Merz CN; Pepine CJ; Walsh MN; Fleg JL Circulation; 2017 Mar; 135(11):1075-1092. PubMed ID: 28289007 [TBL] [Abstract][Full Text] [Related]
88. Fractional flow reserve-guided percutaneous coronary intervention: does coronary pressure never lie? van de Hoef TP; van Lavieren MA; Henriques JP; Piek JJ; Claessen BE Curr Treat Options Cardiovasc Med; 2014 Apr; 16(4):294. PubMed ID: 24515354 [TBL] [Abstract][Full Text] [Related]
89. Fractional flow reserve as a surrogate for inducible myocardial ischaemia. van de Hoef TP; Meuwissen M; Escaned J; Davies JE; Siebes M; Spaan JA; Piek JJ Nat Rev Cardiol; 2013 Aug; 10(8):439-52. PubMed ID: 23752699 [TBL] [Abstract][Full Text] [Related]